KAEL–GemVax Reports Significant Interim Progress In UK Telovac Phase III Study Of GV1001 Anti-Telomerase Vaccine In Pancreatic Cancer

OSLO, Norway--(BUSINESS WIRE)--KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major “blockbuster” potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.